spacer
home > ict > summer 2021 > future factories – optimising operations
PUBLICATIONS
International Clinical Trials

Future Factories – Optimising Operations


At the height of the pandemic crisis, the pharma industry faced urgent pressure to accelerate its operations. The planet’s health – quite literally – depended on it. Amid the unprecedented global need for large quantities of inoculations, it became increasingly critical for vaccine producers to take advantage of the recent advances in process digitisation. The world has since benefitted from the remarkably swift development of life-saving COVID-19 vaccines.

Process development (PD) in the pharma industry now involves more data-driven decision-making and risk assessment than ever before. Under new PD models, companies leverage more data, automation, and modelling to reduce risks and establish a holistic, transferable control strategy.

Industry time-to-market is shorter than ever, and development cycle times are shrinking. These process improvements make the industry better able to rise to the challenge of meeting global health needs as they occur, meaning a safer, healthier future for all.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
About the Author

Perry Zalevsky is the Senior Director of the Industry team at AVEVA, which includes the pharmaceutical and life science industries. With over 30 years of experience working with a variety of companies, on process and product improvement projects, Perry has developed a number of mathematical and AI-based models to help with business and manufacturing/ operational enhancements. He has previously worked at SAP as an Industry Principal, and prior to that at other supply chain software companies. Perry holds a BSc in Applied Mathematics and an MSc degree in Operations Research, both from Carnegie Mellon University in Pittsburgh, Pennsylvania, US.
Print this page
Send to a friend
Privacy statement
News and Press Releases

Cellares and Poseida Therapeutics Partner to Accelerate Cell Therapy

SOUTH SAN FRANCISCO – July 14, 2021 – Cellares Corporation, a life sciences technology company pioneering a revolutionary automated approach to cell therapy manufacturing, today announced that Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create cell and gene therapeutics with the capacity to cure, has joined its Early Access Partnership Program (EAPP). Poseida is the third organization to participate in Cellares’ EAPP, following industry partner PACT Pharma and academic partner Fred Hutchinson Cancer Research Center.
More info >>

White Papers

PROTEIN:PROTEIN INTERACTION ANALYSIS

IBA GmbH

Groth et al., 2007 and Jasencakova et al., 2010 Protein:protein-interactions (PPI) govern almost all important processes in living organisms. Thus, their rapid and accurate determination and investigation is a major challenge in life sciences. The extremely efficient and fast One-STrEP (Twin-Strep) system is suitable for the isolation of functional protein complexes and subsequent mass spectrometry analysis leads to the identification of protein complex components (Junttila et al., 2005) as it is shown in the following studies.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement